Primer: Sinopharm Group (1099 HK) - Aug 2026
Dominant Market Leader with State Backing: Sinopharm Group is the largest pharmaceutical distributor in China, benefiting from an extensive...
100 Views
APAC Healthcare Weekly (August 16) – Akeso, Fosun Pharma, CSPC Pharma, Daiichi Sankyo, Peptidream
Akeso’s ivonescimab and Daiichi Sankyo’s Enhertu got additional indications approvals in China. CSPC Pharma’s mpox mRNA vaccine candidate got FDA...
107 Views
Sinopharm Group (1099 HK) – Downgrade to a Sell
​Despite expectations for improvement, growth has slowed with limited positive catalysts in the near term. Pricing pressure, competition in the...
359 Views
Quiddity Leaderboard Hang Seng Index Dec26: Z.AI, COSCO, 3SBIO Among Our Top Picks
We have presented our top 10 picks for addition for HSI in Dec26. In the last 5 rebalances, at least one name has been added from our top 10 picks...
137 Views
APAC Healthcare Weekly (March 15) – Sino Bio, Hengrui, Astellas, Daiichi Sankyo, HK Inno, CSL
Couple of Chinese companies got clinical trials approvals for their respective drug candidates. Astellas’ Phase 3 trial failed to meet primary...
572 Views